Clinical trials: Acute Coronary Disease
Acute Coronary Syndrome, Myocardial Infarction
Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial
Patients who continue to smoke after a heart attack have a 35% increased risk of a recurrent event or death compared with those who quit. Many patients attempt to stop smoking after a heart attack, but relapse rates approach 66%.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Smoking
- Trial name
- ZESCA (NCT00689611)
- Testing
- Bupropion HCl ER
- Where
- 38 sites in United States, Bangladesh and 5 more
- Volunteers
- 392 people
- Sponsor
- Mark Eisenberg
Acute Coronary Syndrome
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE (NCT02525939)
- Testing
- dalcetrapib
- Where
- 557 sites in United States, Argentina and 30 more
- Volunteers
- 6,147 people
- Sponsor
- DalCor Pharmaceuticals
Acute Coronary Syndrome (ACS)
Maintenance of Platelet Inhibition With Cangrelor
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
- Trial name
- Bridge (NCT00767507)
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- The Medicines Company
Acute Kidney Injury
Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery
Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after…
- Trial name
- KIDPROAM (NCT01245595)
- Testing
- Aminophylline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Stanford University
Myocardial Infarction
Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Most of the previous data regarding the efficacy of the everolimus-eluting stent (EES) was derived from studies comparing EES with bare metal stent (BMS) or EES with paclitaxel-eluting (PES).
- Trial name
- EVERZOTA (NCT01347554)
- Testing
- Everolimus eluting stent, Zotarolimus eluting stent
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Yonsei University
Heart Failure, Diabetes
Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart failure remains an increasing cause of morbidity and mortality in the United States even in the face of recent advances in the treatment of cardiovascular disease.
- Trial name
- NCT00680706
- Testing
- Thiamine
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- Baystate Medical Center
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Blood Transfusion Complications
Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications
This study is designed to determine if point-of-care washing of allogeneic Leukocyte-Reduced Red Blood Cells reduces pulmonary complications when compared to standard-of-care Leukocyte-Reduced Red Blood Cells in a cardiac…
- Trial name
- NCT02094118
- Testing
- Point-of-care washed red blood cell transfusion., Standard of care red blood cell transfusion.
- Where
- 2 sites in United States
- Volunteers
- 171 people
- Sponsor
- Mayo Clinic
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
- Trial name
- ABC-HFT (NCT00842023)
- Testing
- Nesiritide, Nitroglycerin
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Western University of Health Sciences
Acute Myocardial Infarction
Bivalirudin Infusion for Ventricular Infarction Limitation
The purpose of this study is to evaluate whether the use of bivalirudin will reduce extent of the damage done to the heart muscle in participants who suffered a heart attack, compared to the comparator treatment (heparin).
- Trial name
- BIVAL (NCT02565147)
- Testing
- PPCI, Bivalirudin, Heparin
- Where
- 4 sites in France, Netherlands
- Volunteers
- 78 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome, Fear
Investigating Fear Of Recurrence as a Modifiable Mechanism of Behavior Change
The primary goal of this project is to identify, measure, and influence fear of cardiac event recurrence, a candidate mechanism of change in medication adherence in patients with suspected acute coronary syndrome (ACS).
- Conditions
- Acute Coronary Syndrome, Fear, Medication Adherence
- Trial name
- INFORM (NCT03853213)
- Testing
- Cognitive Bias Modification Training, Attention Control Training
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Columbia University
Myocardial Ischemia, Acute Coronary Syndrome
Cardiac Rehabilitation for Heart Event Recovery (HER)
The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.
- Conditions
- Myocardial Ischemia, Acute Coronary Syndrome, Heart Disease, Coronary Artery Disease
- Trial name
- CR4HER (NCT01019135)
- Testing
- Cardiac Rehabilitation
- Where
- 5 sites in Canada
- Volunteers
- 169 people
- Sponsor
- University Health Network, Toronto
Acute Coronary Syndrome, Lipid Disorder
Polypill in Acute Coronary Syndrome
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low.
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Trial name
- POLY-ACS (NCT05514938)
- Testing
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Coronary Syndrome
Antithrombotic Effects of Ticagrelor Versus Clopidogrel
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).
- Trial name
- NCT01642238
- Testing
- Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Juan J Badimon
Myocardial Infarction
Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.
- Trial name
- REMINDER (NCT01176968)
- Testing
- Eplerenone
- Where
- 75 sites in Canada, Czechia and 9 more
- Volunteers
- 1,012 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Stroke
Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke
The purpose of this study is to determine if external counterpulsation (ECP) is feasible to perform, tolerable, and safe as a treatment for patients with acute ischemic stroke (i.e., a blockage of one of the arteries supplying a…
- Trial name
- CUFFS (NCT00983749)
- Testing
- Full-pressure ECP
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Diego
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome, Depressive Symptoms
Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes
The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.
- Trial name
- CODIACSQoL (NCT01993017)
- Testing
- Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care
- Where
- 4 sites in United States
- Volunteers
- 1,501 people
- Sponsor
- Columbia University